News

The Phase IIa proof-of-concept study is designed to evaluate tumor response in addition to safety and tolerability of Prolarix in 14 patients with non-resectable hepatocellular carcinoma who have

According to the company, the expanded Vyvanse dosing options will allow physicians to individualize treatment for each patient. Vyvanse, which received FDA approval for the treatment of attention

As part of the Healthy Ambition program, Crucell’s operational excellence program, the formulation, filling and packaging of Dukoral in Sweden will stop during 2011 and will move to

This technology, which provides detailed characterization of expressed protein-encoding genes, identifies many non-coding RNAs, and includes sample multiplexing capability, is expected to be available for limited release through

The Echocardiography guided Cardiac Resynchronization Therapy (EchoCRT) study, a prospective, randomized, double-blind, international, multicenter clinical trial of its kind will randomize more than 1,250 patients with heart failure,

The patent encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases. VioQuest Pharmaceuticals licensed rights to Lenocta (sodium stibogluconate) from

Mr Quan joins MHB with experience across several industries where he played roles including founder, director and board member. Mr Quan has undertaken the responsibility to strengthen the

Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses. Columbia intends to use the net proceeds from the offering for general corporate purposes,

The Phase II study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare